Viral Hepatitis
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 1, 2004; 10(3): 389-392
Published online Feb 1, 2004. doi: 10.3748/wjg.v10.i3.389
Viral replication modulated by synthetic peptide derived from hepatitis B virus X protein
Chang-Zheng Song, Qing-Wei Wang, Chang-Cheng Song, Zeng-Liang Bai
Chang-Zheng Song, Zeng-Liang Bai, Laboratory of Immunobiology, College of Life Sciences, Shandong University, Jinan 250100, Shandong Province, China
Chang-Zheng Song, Shandong Research Center for Medical Biotechnology, Shandong Academy of Medical Sciences, Jinan 250062, Shandong Province, China
Qing-Wei Wang, Cancer Research Center, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China Chang-Cheng Song, Basic Research Laboratory, National Cancer Institute at Frederick, MD 21702, USA
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Chang-Zheng Song, Project of Viral Vaccine, Shandong Research Center for Medical Biotechnology, Shandong Academy of Medical Sciences, Jinan 250062, Shandong Province, China. songcz@life.sdu.edu.cn
Telephone: +86-531-2919607
Received: August 6, 2003
Revised: September 15, 2004
Accepted: September 24, 2004
Published online: February 1, 2004
Abstract

AIM: A strategy for viral vaccine design is the use of conserved peptides to overcome the problem of sequence diversity. At present it is still unclear whether conserved peptide is safe as a candidate vaccine. We reported it here for the first time not only to highlight the biohazard issue and safety importance for viral peptide vaccine, but also to explore the effect of a fully conserved peptide on HBV replication within the carboxyl terminus of HBx.

METHODS: We synthesized the fully conserved peptide (CP) with nine residues, FVLGGCRHK. HBV-producing 2.2.15 cells were treated with or without 3.5 μM CP for 36 hours. Quantitative detection of viral DNA was performed by real-time PCR. HBV antigens were determined by enzyme-linked immunoadsorbent assay (ELISA). Quantitative analyses of p53 and Bax proteins were based on immunofluorescence. Flow cytometry was performed to detect cell cycle and apoptosis.

RESULTS: Both extracellular and intracellular copies of HBV DNA per ml were significantly increased after incubation with 3.5 μM of CP. HBsAg and HBeAg in the cultured medium of CP-treatment cells were as abundant as untreated control cells. CP influenced negatively the extracellular viral gene products, and 3.5 μM CP could significantly inhibit intracellular HBsAg expression. In response to CP, intracellular HBeAg displayed an opposite pattern to that of HBsAg, and 3.5 μM CP could efficiently increase the level of intracellular HBeAg. Flow cytometric analyses exhibited no significant changes on cell cycle, apoptosis, p53 and Bax proteins in 2.2.15 cells with or without CP.

CONCLUSION: Together with the results generated from the synthetic peptide, we address that the conserved region, a domain of HBx, may be responsible for modulating HBV replication. As conserved peptides from infectious microbes are used as immunogens to elicit immune responses, their latent biological hazard for human beings should be evaluated.

Keywords: $[Keywords]